A Phase I, Multicenter, Open-Label, Parallel-Group Adaptive Pharmacokinetic Single Dose Study of Oral Lasmiditan in Subjects With Normal and Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors CoLucid Pharmaceuticals; Eli Lilly
- 25 Jul 2017 Status changed from recruiting to completed.
- 16 Mar 2017 Status changed from not yet recruiting to recruiting.
- 01 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Mar 2017.